Navigation Links
Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
Date:6/30/2010

fer and provide contact with its network of physicians and patient organizations. The purchase price is undisclosed but divided into an up-front payment and commercial milestone payments.

The PPS product opportunity is an important means to provide a treatment to a patient group largely suffering without effective medication and to expand sales of immunoglobulin in new patient segments.

About PPS

Several decades after suffering acute polio infection survivors commonly develop PPS characterized by new or increased muscle weakness, fatigue, and pain. Ongoing denervation is the most often suggested for increased muscle weakness associated with polio infection.

Patients with PPS have increased expression of mRNA for proinflammatory cytokines in cerebrospinal fluid which suggests an inflammatory process in the central nervous system. Some patients with asymmetrical weakness have increased wear and tear on joints and muscles, including breathing muscles.

While rarely fatal, the neurological and muscular symptoms of PPS are lifelong and debilitating.

The most recent polio epidemic culminated in the Western countries around 1950. As most infections occur in children, there is nowadays a large pool of polio survivors with varying degrees of functional decline. US National Institute of Neurological Disorders and Stroke (NINDS) gives a prevalence interval for PPS of 25 to 50% (in primary polio infection survivors), WHO estimates a 40 % prevalence; assuming a prevalence of 30%, only in major Western countries there would be around 300,000 PPS patients.

Currently there is no pharmacological treatment for PPS. Several therapeutic agents have failed in achieving positive outcomes. Treatment practices are based on physiotherapy
'/>"/>

SOURCE Pharmalink AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... two investor conferences in the month of September.  ... Officer, will present at Rodman & Renshaw,s 17th Annual ... 10:25am ET/7:25am PT at the St. Regis Hotel in ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's ... narrows down the product choices to a manageable shortlist of bench and floor ... to models that fit best with the customer’s industry and application. , ...
(Date:8/26/2015)... Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Emerging Growth Conference on ... held at the New York Marriott Marquis. ... available through the investor relations section of Roka Bioscience,s ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
Breaking Biology Technology:Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2METTLER TOLEDO Updates Online Scale Selection Tool 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology and medical ... China and the United,States, today announced that it ... of Strategy., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ... worked at Pfizer Inc., where,she co-led Pfizer,s venture ...
... Free access to 'Best Practices for Long-term ... R. Rajagopal's highly successful November 2007 position ... Option', is being offered. It emphasizes the ... as it nears commercialization as a viable ...
... July 10 Pinnacle Biologics, a,private, full-service pharmaceutical ... into an agreement with pharmexx to expand sales,support ... Europe. Terms of the,agreement were not disclosed., ... "We are,pleased to conclude this agreement with pharmexx, ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 2Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 3Comprehensive Jatropha Standards Mandatory in Optimum Long-term Biofuel Efficacy 4Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets 2
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... May 28, 2008 Oslo SEVEN pioneering scientists ... nanoscience, neuroscience and astrophysics have become the first recipients ... selected for their groundbreaking research that has significantly advanced ... an ultra-small scale, the basic circuitry of the human ...
... a contract signed today, the European Commission has ... decide upon the best way to unite Europes ... network for the life sciences. The European Life-science ... by the European Molecular Biology Laboratorys European Bioinformatics ...
... is available in Spanish . , ... suffering cardiovascular diseases. For her doctoral thesis, University of ... the effects of substitute treatments and the genetic factors ... is a natural period in the ageing process of ...
Cached Biology News:Names of inaugural Kavli Prize winners revealed 2Names of inaugural Kavli Prize winners revealed 3Securing the future of Europe's biological data resources 2Quest for better treatment for effects of menopause 2Quest for better treatment for effects of menopause 3
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... A multi-purpose, high gel-strength agarose suitable for ... from conventional constant field to Pulsed Field ... gel strength and exclusion limits, Multi ABgarose ... reduced running times. This in turn means ...
... molecular screening, low melting point agarose where ... is recommended for separation of nucleic acids ... PCR products. Micro ABgarose is also suited ... for blotting techniques. At a 3% concentration, ...
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Biology Products: